Remove tag biomarker
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. There were also personalised care-related unmet needs identified, and this included the need for better predictive biomarkers. Cost-related unmet needs also scored highly.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Among the patients treated at the RP2D, six out of seven had reduction or stabilisation of serum-free light chains – a biomarker that indicates the presence of myeloma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Owkin taps Linux Foundation to open-source its AI learning software

pharmaphorum

Owkin in particular has bagged some high-profile, high-price tag development deals with the likes of Bristol-Myers Squibb and Sanofi. The results of the collaboration were announced earlier this year, showing that the collaboratively trained AI outperformed single-partner models on multiple axes.

article thumbnail

How data is crucial to the relaunch of the Cancer Moonshot

pharmaphorum

Participants can also receive tumour biomarker testing that may help offer them different treatment options. Another hurdle would be to create resources on a public-facing website for consent forms and access to biomarker reports, which would also need to be engaging and easy to navigate.

article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

BT-474 cell line was gene-edited to incorporate a green fluorescent protein (GFP) tag into late endosomes/lysosomes (green). MDC’s strategy is focused on cellular sciences, target engagement, biomarkers, and drug delivery and biodistribution. Physical characterisation.